Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated just now
Peer-reviewedCC BY 4.0PLOS Medicine

Effectiveness of pneumococcal vaccination campaigns in humanitarian settings: A modelling study

3 more authors
7 affiliations
  1. 1Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom
  2. 2Health and Nutrition, Save the Children International, Hargeisa, Somaliland
  3. 3Republic of Somaliland Ministry of Health Development, Hargeisa, Somaliland
  4. 4Save the Children, London, United Kingdom
  5. 5Infection, Immunity and Global Health, Murdoch Children’s Research Institute, The University of Melbourne Department of Paediatrics at the Royal Children’s Hospital, Melbourne, Australia
  6. 6Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
  7. 7Centre for Global Health, Charité - Universitätsmedizin Berlin, Berlin, Germany

Abstract

Background: A large and increasing number of people are forcibly displaced worldwide because of war, food insecurity, and other crises. Streptococcus pneumoniae likely causes a substantial health burden in crisis-affected populations. Pneumococcal conjugate vaccines (PCVs) are widely used in routine immunisation programmes, including through the Essential Programme on Immunization (EPI) to protect against pneumococcal disease. They are typically administered as a three-dose schedule, either as three doses in early infancy or two doses in infancy followed by a booster at 9–18 months of age. However, PCVs are rarely used in humanitarian responses. We evaluated the potential impact of logistically feasible PCV campaigns in such settings. Methods and findings: We conducted a pneumococcal carriage, malnutrition, and social contact survey in a camp for displaced people near Hargeisa, Somaliland, to parameterise a transmission model accounting for migration. We projected the effect of PCV mass-vaccination campaigns using one or two doses and vaccinating children <1, 2, 5, 10, or 15 years (y) of age in the Somaliland camp and three different crisis settings. We found that a single-dose PCV campaign with high vaccine coverage in children <5 y or older can partially control vaccine-serotypes for up to 3 y, preventing 27% (95% CrI: 20, 34) of severe pneumococcal disease, defined as a composite of invasive pneumococcal disease and nonbacteraemic pneumonia, when vaccinating <5 y olds and 38% (95% CrI: 29, 46) when vaccinating <15 y olds. Expanded age eligibility is needed for comparable protection in settings with increased migration or more interaction with unvaccinated host populations. A campaign vaccinating <5 y olds is the most efficient use of PCV with 108 (95% CrI 77–162) vaccines needed to prevent one case of severe pneumococcal disease. Implementing such campaigns in displaced populations worldwide would require about 30 million doses in the next 5 y. Key limitations included sparse empirical data on PCV effectiveness and pneumococcal disease in humanitarian settings, and extrapolation of Somaliland carriage and contact patterns to other crisis settings. Conclusions: Single-dose mass-vaccination campaigns offer crisis-affected populations an effective, pragmatic immunisation strategy to deliver PCVs if routine EPI services have been disrupted. Why was this study done?: What did the researchers do and find?: What do these findings mean?: In a modelling study, Kevin van Zandvoort and colleagues find that a single dose of pneumococcal vaccine in children less than 5 yrs could protect against severe disease in humanitarian settings where routine immunization is disrupted.

Related

  1. Pneumococcal nasopharyngeal carriage, serotype distribution, and vaccination status in hospitalized children in Latvia: A cross-sectional study during the post-PCV13, pre-PCV15/PCV20 transition period
    Hedija Cupeca, Indra Zeltina, Anita Villerusa +7
    PLOS OnePeer-reviewedCC BY 4.0Full textImmunologyMicrobiologyPLOS
  2. Reinforced strategies versus standard pneumococcal vaccination regimen in patients with ANCA-associated vasculitides receiving rituximab therapy: A Multicenter Randomized Controlled Trial
    Benjamin Terrier, Laura Richert, Grégory Pugnet +34
    Clinical Microbiology and InfectionPeer-reviewedCC BYImmunologyGeneral medicineHAL
  3. Real-world effectiveness of maternal genetically inactivated acellular pertussis vaccination in protecting infants under three months of age: a case-control study using concurrent community-based and test-negative controls
    Farooq Phiriyasart, Virasakdi Chongsuvivatwong, Ponlagrit Kumwichar
    InfectionPeer-reviewedCC BY 4.0Full text1 citedMicrobiologyPMC
  4. Cost-effectiveness and budget impact analyses of strategies to improve measles vaccination coverage in Kenya
    Stacey Orangi, Prashant Mandaliya, Rose Jalang’o +6
    PLOS Global Public HealthPeer-reviewedCC BY 4.0Full textImmunologyEpidemiology & public healthPLOS
  5. Effectiveness of the PPR Sungri-96 Vaccine in Sheep and Goats in India: A Nationwide Post-Vaccination Seromonitoring Study Towards PPR Elimination.
    Vinayagamurthy Balamurugan, Kirubakaran Vinod Kumar, Rakshit Ojha +19
    VirusesPeer-reviewedCC BYFull textPlant biologyEurope PMC
BibTeX
@article{zandvoort2026effectiveness,
  title = {{Effectiveness of pneumococcal vaccination campaigns in humanitarian settings: A modelling study}},
  author = {Kevin van Zandvoort and Mohamed O. Bobe and Abdirahman I. Hassan and Rachael Cummings and Abdihamid Warsame and Casey L. Pell and Mohamed Ismail Abdi and Saed Ibrahim and Catherine R. McGowan and E. Kim Mulholland and Catherine Satzke and Rosalind M. Eggo and Mohamed Abdi Hergeye and Francesco Checchi and Stefan Flasche},
  journal = {PLOS Medicine},
  year = {2026},
  month = nov,
  doi = {10.1371/journal.pmed.1004768},
  url = {https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004768},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Effectiveness of pneumococcal vaccination campaigns in humanitarian settings: A modelling study
AU  - Kevin van Zandvoort
AU  - Mohamed O. Bobe
AU  - Abdirahman I. Hassan
AU  - Rachael Cummings
AU  - Abdihamid Warsame
AU  - Casey L. Pell
AU  - Mohamed Ismail Abdi
AU  - Saed Ibrahim
AU  - Catherine R. McGowan
AU  - E. Kim Mulholland
AU  - Catherine Satzke
AU  - Rosalind M. Eggo
AU  - Mohamed Abdi Hergeye
AU  - Francesco Checchi
AU  - Stefan Flasche
PY  - 2026
DA  - 2026/11/11
JO  - PLOS Medicine
DO  - 10.1371/journal.pmed.1004768
UR  - https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004768
AB  - Background: A large and increasing number of people are forcibly displaced worldwide because of war, food insecurity, and other crises. Streptococcus pneumoniae likely causes a substantial health burden in crisis-affected populations. Pneumococcal conjugate vaccines (PCVs) are widely used in routine immunisation programmes, including through the Essential Programme on Immunization (EPI) to protect against pneumococcal disease. They are typically administered as a three-dose schedule, either as three doses in early infancy or two doses in infancy followed by a booster at 9–18 months of age. However, PCVs are rarely used in humanitarian responses. We evaluated the potential impact of logistically feasible PCV campaigns in such settings. Methods and findings: We conducted a pneumococcal carriage, malnutrition, and social contact survey in a camp for displaced people near Hargeisa, Somaliland, to parameterise a transmission model accounting for migration. We projected the effect of PCV mass-vaccination campaigns using one or two doses and vaccinating children <1, 2, 5, 10, or 15 years (y) of age in the Somaliland camp and three different crisis settings. We found that a single-dose PCV campaign with high vaccine coverage in children <5 y or older can partially control vaccine-serotypes for up to 3 y, preventing 27% (95% CrI: 20, 34) of severe pneumococcal disease, defined as a composite of invasive pneumococcal disease and nonbacteraemic pneumonia, when vaccinating <5 y olds and 38% (95% CrI: 29, 46) when vaccinating <15 y olds. Expanded age eligibility is needed for comparable protection in settings with increased migration or more interaction with unvaccinated host populations. A campaign vaccinating <5 y olds is the most efficient use of PCV with 108 (95% CrI 77–162) vaccines needed to prevent one case of severe pneumococcal disease. Implementing such campaigns in displaced populations worldwide would require about 30 million doses in the next 5 y. Key limitations included sparse empirical data on PCV effectiveness and pneumococcal disease in humanitarian settings, and extrapolation of Somaliland carriage and contact patterns to other crisis settings. Conclusions: Single-dose mass-vaccination campaigns offer crisis-affected populations an effective, pragmatic immunisation strategy to deliver PCVs if routine EPI services have been disrupted. Why was this study done?: What did the researchers do and find?: What do these findings mean?: In a modelling study, Kevin van Zandvoort and colleagues find that a single dose of pneumococcal vaccine in children less than 5 yrs could protect against severe disease in humanitarian settings where routine immunization is disrupted.
SN  - 1549-1676
ER  -